Inj, cabote rilpivir 2mg 3mg
Products billed under this code include Cabenuva.
Payment limit per 2MG/3MG, by effective quarter, 4Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Cabenuva.
Payment limit per 2MG/3MG, by effective quarter, 4Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cabenuva | ViiV Healthcare Company | 49702-0240-15 | 300 | $7,394.70 |
| Cabenuva | ViiV Healthcare Company | 49702-0253-15 | 200 | $4,929.80 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $24.649 | −$0.018 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted September 17, 2026 |
| 3Q26 | $24.667 | +$0.486 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted September 15, 2026 |
| 2Q26 | $24.181 | +$0.017 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted September 15, 2026 |
| 1Q26 | $24.164 | +$0.515 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted September 15, 2026 |
| 4Q25 | $23.649 | +$0.02 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted September 8, 2026 |
| 3Q25 | $23.629 | +$0.497 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted March 10, 2026 |
| 2Q25 | $23.132 | −$0.042 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted March 10, 2026 |
| 1Q25 | $23.174 | +$0.273 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted December 19, 2025 |
| 4Q24 | $22.901 | −$0.023 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted June 11, 2025 |
| 3Q24 | $22.924 | +$0.307 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted June 11, 2025 |
| 2Q24 | $22.617 | +$0.02 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted March 11, 2025 |
| 1Q24 | $22.597 | +$0.311 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted December 19, 2024 |
| 4Q23 | $22.286 | +$0.444 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted October 10, 2024 |
| 3Q23 | $21.842 | +$0.287 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted June 5, 2024 |
| 2Q23 | $21.555 | −$0.005 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted February 23, 2024 |
| 1Q23 | $21.56 | +$0.497 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted December 6, 2023 |
| 4Q22 | $21.063 | +$0.01 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted June 22, 2023 |
| 3Q22 | $21.053 | +$0.51 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted June 9, 2023 |
| 2Q22 | $20.543 | −$0.013 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted December 14, 2022 |
| 1Q22 | $20.556 | +$0.001 | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted June 8, 2022 |
| 4Q21 | $20.555 | – | 2MG/3MG | Inj, cabote rilpivir 2mg 3mg | v1, posted June 2, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.